Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Wockhardt

F&O Talk: Nifty may consolidate further; Sudeep Shah's strategy on TCS, HDFC Bank, Infosys

Indian stock markets, Sensex and Nifty, closed lower following the RBI's hawkish stance, despite falling oil prices. Analyst Sudeep Shah anticipates a consolidation phase for Nifty, with key support at 23,100-23,050 and resistance at 23,550-23,600. Bank Nifty shows resilience, while IT stocks underperform.

The Economic Times

CG Power's growth momentum strong, but valuation comfort missing: Sandip Sabharwal

CG Power expands its switchgear production, signaling strong demand in the power equipment sector. However, market expert Sandip Sabharwal warns that valuations for companies like CG Power, Hitachi Energy, and GE Vernova have surged significantly. He advises existing investors to hold but suggests new investors wait for corrections. Wockhardt's Zaynich…

The Economic Times

Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?

Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for urinary tract infections. The company also reported a strong turnaround in its March quarter results. Revenue and profit saw significant year-on-year growth. Biotech operations were a key driver…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Ahead of Market: 10 things that will decide stock market action on Tuesday

Benchmark indices Sensex and Nifty fell for a fourth straight session amid elevated crude oil prices, geopolitical tensions and persistent selling pressure. Market breadth remained weak, technical indicators turned bearish, while select stocks including Wockhardt and NMDC Steel attracted buying interest and hit fresh highs.

The Economic Times

Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details

Wockhardt's shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam, demonstrated superior efficacy over meropenem in a Phase 3 trial. This approval addresses the growing challenge of antimicrobial resistance.

The Economic Times

Ahead of Market: 10 things that will decide stock market action on Monday

Indian equity markets ended sharply lower on May 29 amid broad-based selling, MSCI-driven flows and rising volatility. Technical indicators suggest a bearish bias with key support zones in focus. Global cues, monsoon outlook and market breadth will be critical in shaping investor sentiment and near-term market direction.

The Economic Times

Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibiotic

Wockhardt shares surged after the company received CDSCO approval for its breakthrough antibiotic Zaynich in India. Strong Phase 3 trial results and the drug’s potential to treat severe drug-resistant infections boosted investor sentiment, helping the stock extend recent gains despite technically entering overbought territory after a sharp rally.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Geopolitical tensions keep markets nervous despite strong earnings: Dipan Mehta

Geopolitical tensions, particularly the Iran crisis, are overshadowing strong corporate earnings, according to Dipan Mehta. While India Inc. shows resilience with encouraging results from auto, NBFC, and FMCG sectors, investors remain cautious. Mehta advises selectively accumulating quality businesses available at reasonable valuations amidst this uncertainty, highlighting potential in tech, auto…

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.